Albumin-binding capacity (ABiC) is reduced in patients with chronic kidney disease along with an accumulation of protein-bound uraemic toxins | Zendy

Sebastian Klammt | Zendy; H.-J. Wojak | Zendy; Andrea Mitzner | Zendy; Sebastian Koball | Zendy; Joachim Rychly | Zendy; Emil C. Reisinger | Zendy; Steffen Mitzner | Zendy

Open Access

Albumin-binding capacity (ABiC) is reduced in patients with chronic kidney disease along with an accumulation of protein-bound uraemic toxins

Author(s) -

Sebastian Klammt,

H.-J. Wojak,

Andrea Mitzner,

Sebastian Koball,

Joachim Rychly,

Emil C. Reisinger,

Steffen Mitzner

Publication year - 2011

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfr616

Subject(s) - medicine , kidney disease , albumin , plasma protein binding , binding protein , endocrinology , biochemistry , pharmacology , chemistry , gene

Albumin is an important transport protein for non-water-soluble protein-bound drugs and uraemic toxins. Its transport capacity is reduced in patients with advanced chronic kidney disease (CKD) and unbound fractions of uraemic toxins are related to complications of CKD. We investigated whether this reduction could be quantified and how it correlated with the stages of CKD. Albumin-binding capacity (ABiC) is a dye-based method that quantifies the remaining binding capacity of one major binding site (site II) of the albumin molecule.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research